News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
* AstraZeneca PLC (AZN [https://seekingalpha.com/symbol/AZN]) declares a $1.06/share interim dividend [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html]. * Payable Sept. 8; for shareholders of record Aug. 7; ex-div Aug. 7. * Looking ahead for FY 2026, the company intends to increase its total annual dividend payout to $3.30 per share. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%[Seeking Alpha] Seeking Alpha (Seeking Alpha) MORE ON ASTRAZENECA PLC * AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback [https://seekingalpha.com/article/4922348-astrazeneca-oncology-engine-keeps-running-despite-wainua-setback] * AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic [https://seekingalpha.com/article/4921003-astrazeneca-and-ionis-pharma-rocked-by-heart-disease-fail-why-you-shouldnt-panic] * AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%* AstraZeneca PLC press release [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html] (AZN [https://seekingalpha.com/symbol/AZN]): Q2 Non-GAAP EPS of $2.63 beats by $1.36. * Revenue of $15.38B (+6.4% Y/Y) misses by $50M. * Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK). * FY2026 Revenue estimated growth …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca's shares rose after the drugmaker reported better-than-expected second-quarter earnings, driven by strong growth in oncology and rare diseases. Despite a recent trial failure that impacted its valuation, the company reiterated its full-year revenue and core earnings per share growth outlook. CEO Pascal Soriot …
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues. Looking ahead for fiscal 2026, AstraZeneca continues to expect total revenue to increase by a mid-to-high single-digit percentage, and core earnings per share …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%This article provides a brief earnings snapshot for Astrazeneca's Q2 results. However, the actual financial details and performance metrics are not included in the provided text.
AstraZeneca reported a 6% increase in its second-quarter revenue, reaching $15.4 billion. This financial update indicates continued growth for the pharmaceutical company.
AstraZeneca PLC (AZN.L) reported its H1 revenue to be $30.67 billion. This financial update comes alongside recent news regarding the company's drug trials, including Ultomiris missing its primary endpoint in a late-stage trial. Despite some setbacks, AstraZeneca posted a rise in H1 profit and …
(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026. AstraZeneca, as a biopharmaceutical company, offers multiple products for oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and therapies for rare diseases. AstraZeneca's blockbuster …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca PLC's stock (AZN) closed at $169.260, up 0.43% on July 24th, with a market capitalization of $525.04B. Despite recent market underperformance, the company boasts healthy fundamentals, high growth potential, and significant institutional ownership. Analysts maintain a "Buy" rating with a target price indicating …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AstraZeneca PLC (AZN) after the company announced its Phase-3 CARDIO-TTransform trial for Wainua failed to meet its primary endpoint. This news led to a 5.7% drop in AstraZeneca's American Depositary …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, HER2-negative advanced breast cancer. The decision is based on Phase III SERENA-6 trial …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer. The EC approved Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca's Enhertu plus pertuzumab would become …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca PLC is projected to report earnings of $2.54 per share. This information comes from a Refinitiv earnings preview.
Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%The European Union has approved AstraZeneca's drug Etcamah. This approval comes as the United States' decision on the drug is still pending. The article highlights this significant regulatory milestone for AstraZeneca.
AstraZeneca's Etcamah (camizestrant), combined with a CDK4/6 inhibitor, has received EU approval for the 1st-line treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer demonstrating an emergent ESR1 mutation and no disease progression on endocrine therapy. This approval is based …
(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union or EU for the treatment of adult patients for an advanced breast …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca's Etcamah (camizestrant), in combination with a CDK4/6 inhibitor, has received approval in the EU for treating adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation. This approval, based on the SERENA-6 Phase III trial, demonstrated a 56% …
Sharemaestro market context Price below Trend Line 52 weeks -1.4%Jefferies believes that forthcoming detailed data on AstraZeneca's experimental lung drug, tozorakimab, could mitigate the impact of a recent heart trial failure. The bank reiterated its "buy" rating and a 17,500p price target, citing the drug's potential to treat chronic obstructive pulmonary disease regardless …
Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.50 per share in its upcoming report, which indicates a year-over-year increase of 14.7%. Revenues are expected to be $15.31 billion, up 5.9% from the year-ago quarter. The current level reflects a downward …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%This article provides an earnings preview for AstraZeneca (AZN), stating that the pharmaceutical giant is scheduled to report its financial results on July 27. Investors will be closely watching for details on the company's performance, including revenue growth from new drug launches and overall …
JP Morgan analyst Richard Vosser has reaffirmed a "Buy" rating for AstraZeneca PLC, keeping the target price unchanged at GBX 12380. The pharmaceutical company's stock shows a 0.90% increase, with recent news including Novartis's strong profit and various updates in the biotech sector. AstraZeneca's …
AstraZeneca PLC (AZN) shares fell 1.70% on Monday, closing at £123.80, underperforming the broader market as the FTSE 100 Index declined 0.71%. The company's stock is now 21.31% below its 52-week high of £157.32, which was reached on February 18th.
Astrazeneca (AZN) experienced a more significant drop than the broader market, closing down 2.59% while the S&P 500 had a smaller loss. Over the past month, AZN's stock fell 3.45%, underperforming both the Medical sector and the S&P 500. Investors are anticipating its upcoming …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion …
Sharemaestro market context Price below Trend Line 52 weeks -4.0%Search by ticker symbol or company name and select a result to open its chart.